End Of US FDA’s ‘Two-Trial Dogma’ Places Faith In Modern Science Of Evidence

 
• By Bridget Silverman
  
The FDA's default expectation will no longer be that two clinical trials are needed to support approval. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards